Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort
British Journal of Clinical Pharmacology · 2023-10 · 89 (10) · 3209-3216
DOI: 10.1111/bcp.15827 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 26.06.2023. Verfasst von Bianza Tinotenda Mbavha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, African Institute of Biomedical Science and Technology (AiBST), Beatrice, Zimbabwe. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, European and Developing Countries Clinical Trials Partnership.
Abstract (Originalsprache)
Tamoxifen is the most used hormonal therapy for oestrogen receptor‐positive breast cancer. CYP2D6 is the main enzyme in the metabolic pathway of tamoxifen to endoxifen. Variations in endoxifen plasma concentrations are associated with CYP2D6 polymorphisms. This study aimed to determine the association between the CYP2D6 polymorphisms and endoxifen plasma concentrations in a cohort of Zimbabwean breast cancer patients ( n = 40). TaqMan genotyping and copy number assays were done to determine CYP2D6 genotypes. Tamoxifen and metabolites were quantitated using LC‐MS/MS. The population had high frequencies of the CYP2D6 reduced function alleles, *17 (15%) and *29 (18%). The median endoxifen concentration was 4.78 ng/mL, and in 55% of the patients, mostly intermediate metabolizers were below the endoxifen therapeutic threshold of 5.97 ng/mL. The CYP2D6 phenotypes and activity scores were significantly associated with endoxifen plasma concentrations ( P = 0.0151) and with endoxifen to N‐desmethyl‐tamoxifen ratios ( P = 0.0006).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genomic Medicine, African Institute of Biomedical Science and Technology (AiBST), Beatrice, Zimbabwe.
- Department of Biotechnology, Chinhoyi University of Technology, Chinhoyi, Zimbabwe.
- Parirenyatwa Hospital Radiotherapy and Oncology Center, Harare, Zimbabwe.
- Sydney Brenner Institute for Molecular Bioscience (SBIMB), University of the Witwatersrand, Johannesburg, South Africa.
ORCID-Profile: Roslyn Stella Thelingwani
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- European and Developing Countries Clinical Trials Partnership
- Bill and Melinda Gates Foundation
- National Institutes of Health
Zitieren
APA
Mbavha, B. T., Thelingwani, R. S., Chikwambi, Z., Nyakabau, A. M., Masimirembwa, C., & the Consortium for Genomics and Therapeutics in Africa (2023). Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British Journal of Clinical Pharmacology, 89(10), 3209-3216. https://doi.org/10.1111/bcp.15827
Vancouver
Mbavha BT, Thelingwani RS, Chikwambi Z, Nyakabau AM, Masimirembwa C, the Consortium for Genomics and Therapeutics in Africa. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British Journal of Clinical Pharmacology. 2023;89(10):3209-3216. doi:10.1111/bcp.15827
BibTeX
@article{Mbavha2023,
author = {Mbavha, Bianza Tinotenda and Thelingwani, Roslyn Stella and Chikwambi, Zedias and Nyakabau, Anna Mary and Masimirembwa, Collen and the Consortium for Genomics and Therapeutics in Africa, the Consortium for Genomics and Therapeutics in Africa},
title = {Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
volume = {89},
number = {10},
pages = {3209--3216},
doi = {10.1111/bcp.15827}
}
EUVIMED